Kissei Introduces Iktos AI Drug Discovery System

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa, "Kissei") has introduced Makya™, an AI drug discovery system from Iktos (Head Office: Paris, France; Co-Founder and CEO: Yann Gaston-Mathé, "Iktos").

This will enable the rapid design of new small molecules suitable for target criteria using AI technology, leading to an increase in the speed of drug discovery and development.

"Iktos has cutting-edge AI technology in small molecule drug discovery research, and their focus on further small molecule drug discovery technology development fits well with our strategy." said Mutsuo Kanzawa, CEO of Kissei. "We are very pleased that this collaboration will enhance our MedChem capabilities, create innovative compounds with competitive advantages, and lead to shorter compound discovery times."

"We are excited and proud to join forces with Kissei, a leading Japanese pharmaceutical company and to have their scientists use our software in their drug discovery projects", said Yann Gaston-Mathé, Co-founder and CEO of Iktos. "At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of small molecule discovery by combining our powerful algorithmic technology, our know-how derived from the experience of the many collaborations we have established to date, and an intuitive and user-friendly user interface which is essential to an optimal user experience."

As an R&D-oriented pharmaceutical company, Kissei Pharmaceutical is striving to strengthen its compound creation and evaluation technologies with the aim of creating new drugs that can achieve unprecedented levels of innovation and usefulness. By utilizing AI technology, we will pursue speed and quality in drug discovery research by utilizing AI technology to realize the creation of innovative new drugs.

《 Reference 》

About Iktos
Incorporated in October 2016, Iktos is a French start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry, and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos's proprietary AI technology for retrosynthesis.
http://www.iktos.ai/